Trials / Completed
CompletedNCT02756637
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 634 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after curative treatment for BC and 2) that baseline NLR is correlated with the survival benefit of NAC. The study will look at the data from participants of the SWOG 8710 study.
Conditions
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2016-10-01
- Completion
- 2016-11-01
- First posted
- 2016-04-29
- Last updated
- 2023-08-07
- Results posted
- 2017-03-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02756637. Inclusion in this directory is not an endorsement.